Sign up USA
Proactive Investors - Run By Investors For Investors

Aviragen tanks as trial of asthma treatment flops

Aviragen says its trial of asthma treatment vapendavir has failed to meet its primary endpoint.
Aviragen tanks as trial of asthma treatment flops
Aviragen announces results of vapendavir trial

Aviragen Therapeutics (NASDAQ:AVIR) was on the back foot on Tuesday after reporting “disappointing” results for a trial of its asthma treatment, vapendavir.

The NASDAQ-listed drug maker said the Sptiritus phase 2b trial study of vapendavir in treating moderate to severe asthma sufferers with a rhinovirus infection did not meet its primary endpoint.

The treatment failed to demonstrate a “statistically significant” reduction in asthma symptoms at day 14 of the study for the 264 mg or 528 mg dosages, compared to placebo.

“We are disappointed that the Spirtus trial did not meet its primary endpoint in this patient population,” chief executive Joseph Patti, said.

“There was evidence of an antiviral effect in patients that received vapendavir within the first day following the onset of their symptoms, and as such, we plan to take time to fully analyse the data before making a decision on whether to initiate a study in hematopoietic stem cell transplant patients, where the ability to stop the progression of the rhinovirus infection could be beneficial.” 

In early February, Aviragen reported that BTA 585, its drug for the treatment of respiratory syncytial virus infections, flunked in a phase 2a trial.

Shares plunged 34.91% on the NASDAQ in early US trade. 



Register here to be notified of future AVIR Company articles
View full AVIR profile View Profile

Related Articles

picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Stem Cells
March 30 2017
WideCells is aiming to be a major supporting player through its development of a stem cell storage business and, having only listed in London last July, its newsflow so far looks to be pointing the way
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use